Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap

 
• By Brian Yang and Jung Won Shin

Perhaps encouraged by the recent successful initial public offering of Innovent Bio, more biologics developers in China are turning towards innovative biologics and away from traditional biosimilars.

Yuyang garden
New Deal Shows Henlius Turning To Innovative Biologics over Biosimilars • Source: Shutterstock

More from China

More from Focus On Asia